



IFW

TRANSMITTAL FORM (To be used for all correspondence after initial filing)	Application Number	10/797,927
	Filing Date	March 8, 2004
	First Named Inventor	Val Goodfellow
	Art Unit	1614
	Examiner Name	
	Attorney Docket No.	690068.575

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Other Enclosure(s) (please identify below): _____ _____ _____ _____
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Seed Intellectual Property Law Group PLLC	Customer Number 00500	
Signature			
Printed Name	Karl R. Hermanns		
Date	01/03/05	Reg. No.	33,507

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Signature		
Typed or printed name	Jason Añover	Date: 1/03/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 546024



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 3, 2005
Date

Jason Anover
Jason Anover

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Val Goodfellow et al.
Application No. : 10/797,927
Filed : March 8, 2004
For : MELANIN-CONCENTRATING HORMONE RECEPTOR
ANTAGONISTS AND COMPOSITIONS AND METHODS
RELATED THERETO

Art Unit : 1614
Docket No. : 690068.575
Date : January 3, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. Copies of the cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of all other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the

Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC




Karl R. Hermanns
Registration No. 33,507

Enclosures:

Postcard
Form PTO-1449
Cited References (13)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

546028

FORM PTO-1449
(REV. 7-80)

JAN 05 2005

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

690068.575

APPLICATION NO.

10/797,927

APPLICANTS

Val Goodfellow

FILING DATE

March 8, 2004

GROUP ART UNIT

1614

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2002/0052383	05/02/02	Bakthavatchalam et al.	514	255.03	
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AE	WO 01/21169 A1	03/29/01	WIPO		
	AF	WO 01/21577 A2	03/29/01	WIPO		
	AG	2001-226269	08/21/01	JP (+ Abstract in English)		
	AH	WO 01/82925 A1	11/08/01	WIPO		
	AI	WO 01/87834 A1	11/22/01	WIPO		
	AJ	WO 01/94368 A1	12/13/01	WIPO		
	AK	WO 02/04433 A2	01/17/02	WIPO		
	AL	WO 02/06245 A1	01/24/02	WIPO		
	AM	WO 02/059108 A1	08/01/02	WIPO		
	AN	WO 02/070511 A1	09/12/02	WIPO		
	AO	WO 03/031410 A1	04/17/03	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Bednarek, M., <i>et al.</i> , "Synthesis and Biological Evaluation in Vitro of a Selective, High Potency Peptide Agonist of Human Melanin-concentrating Hormone Action at Human Melanin-concentrating Hormone Receptor 1," <i>J. Biol. Chem.</i> 277(16):13821-6, April 19, 2002.
	AQ	Takekawa, S., <i>et al.</i> , "T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist," <i>Eur J Pharmacol.</i> 438(3):129-35, March 8, 2002.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).